Authors: Frank van Leth, Prahpan Phanuphak, Erik Stroes, Brian Gazzard, Pedro Cahn, François Raffi, Robin Wood, Mark Bloch, Christine Katlama, John J. P Kastelein, Mauro Schechter, Robert L Murphy, Andrzej Horban, David B Hall, Joep M. A Lange, Peter Reiss
DOI: 10.1371/journal.pmed.0010019
Abstract Summary
HIV patients starting antiretroviral therapy with nevirapine showed more favorable cholesterol changes than those receiving efavirenz. Nevirapine increased “good” HDL cholesterol by 42.5% versus 33.7% with efavirenz, while raising total cholesterol less. The total-to-HDL cholesterol ratio decreased with nevirapine but increased with efavirenz, suggesting nevirapine-based regimens may lower heart disease risk.
Why Brain? 🧠
Nevirapine shows superior lipid profile benefits over efavirenz in HIV treatment, significantly raising good cholesterol while lowering cardiovascular risk markers, suggesting reduced heart disease risk.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
